A Lesson to Learn o...
Health Care: Drugs
Elan Corp PLC (ELN: NYSE)
$13.78 0.29 | 2.15%
06/18/13 - 04:02 PM ET
Growth Rates
| GROWTH RATES |
|---|
| REVENUE (Trailing 12 Quarters) |
| EARNINGS PER SHARE (Trailing 12 Quarters) |
| DIVIDENDS (Trailing 12 Quarters) |
Portfolios with ELN
- Portfolio NameUser Type
- ContributorMost-Active Stocks for the ...
- ContributorMost-Active Stocks for the ...
- ContributorMost-Active Stocks for the ...
- ProTPG-Axon Capital
- Contributor22 Biopharma Stocks With Br...
- UserGFNN Stockdiagnostics 13
- ContributorBreakout Stocks Of The Week...
- UserGFNN Stockdiagnostics
- ContributorRelative Strength Trades fo...
- ContributorStocks At New 52-Week Highs...
Latest ELN Headlines from TheStreet
- Why This Fund Manager Is Short Ziopharm 03.22.13 | 07:03 am
- SAC to Pay Record Insider Trading Penalty 03.16.13 | 11:03 am
- Dow Sets Another Record as Stocks Rise 03.11.13 | 04:03 pm
- You Have to Love a Lucrative 'Drug Deal' 02.28.13 | 06:02 am
- Royalty Pharma: Don't Let Elan Piss Away $3 Billion On Stupid Acquisitions 02.25.13 | 09:02 am
- 2 Hot Stocks to Trade (or Not) 02.07.13 | 02:02 pm
- Before the Bell: Feb. 6
02.06.13 | 08:02 am - The Digital Skeptic: Insider Trading? Why Even Bother? 12.04.12 | 08:12 am
- SAC's Alleged Insider Trade Hid in Dark Pools 11.20.12 | 03:11 pm
- The Targacept Secret That Wall Street Doesn't Want You to Know About 09.18.12 | 07:09 am
Press Releases for ELN
- Royalty Pharma Announces Firm Offer To Acquire Elan - PR Newswire 04.15.13 | 07:04 am
- New TYSABRI Data Reaffirm Substantial Efficacy In Treatment Of People With MS And Demonstrate Stability Of Anti-JCV Antibody Status - Business Wire 03.18.13 | 07:03 am
- Elan Discloses Filing Of Share Repurchase Tender Offer Documentation - Business Wire 03.12.13 | 01:03 pm
- Elan Provides Update On Tysabri Transaction And $1bn Share Repurchase - Business Wire 03.08.13 | 04:03 pm
- Elan’s Response To Royalty Pharma Statement Of Today - Business Wire 03.06.13 | 09:03 am
- Elan Announces Further Unlocking Of Value To Benefit Shareholders - Business Wire 03.04.13 | 01:03 am
- Elan Announces The Appointment Of Mr. John Given As General Counsel - Business Wire 02.28.13 | 02:02 am
- Elan’s Response To Indication Of Interest - Business Wire 02.25.13 | 09:02 am
- Elan Provides Update Post Restructuring Announcement Of Tysabri Collaboration - Business Wire 02.22.13 | 02:02 am
- Elan Announces Filing Of Annual Report On Form 20-F For Year Ended December 31, 2012 - Business Wire 02.12.13 | 04:02 pm
Partner Headlines for ELN
- Elan Is In Play - Seeking Alpha 06.15.13 | 05:06 am
- Pre-Market Most Active for Jun 14, 2013 : NOK, HIMX, PFE, ELN, BAC, GRPN, BBRY, SCTY, SHG, SIRI, F, MYGN - NASDAQ 06.14.13 | 12:06 pm
- Pre-Market Most Active for Jun 13, 2013 : BLC, SWY, PFE, BAC, FSLR, ELN, VOD, SAN, BBRY, ERIC, SIRI, SPRD - NASDAQ 06.13.13 | 12:06 pm
- Royalty Issues Another Statement Related to Elan Suit - Benzinga 06.11.13 | 09:06 am
- Pre-Market Most Active for Jun 10, 2013 : FB, QQQ, SAN, BAC, ELN, ASX, MT, TSLA, ARMH, SFD, MU, AAPL - NASDAQ 06.10.13 | 12:06 pm
- Benzinga's M&A Chatter for Friday June 7, 2013 - Benzinga 06.09.13 | 11:06 am
- Pre-Market Most Active for Jun 7, 2013 : ELN, BAC, TIVO, TMO, PBF, QQQ, ASX, C, EQIX, FB, JRCC, SIRI - NASDAQ 06.07.13 | 12:06 pm
- Elan's Issues Response to Royalty Pharma Announcement - Benzinga 06.07.13 | 09:06 am
- Elan Rejects Royalty Offer Again - Analyst Blog - Zacks 05.24.13 | 10:05 pm
- Alkermes Earnings Beat Estimates, But Outlook Unclear - Investor's Business Daily 05.23.13 | 06:05 pm
